Project Grant R01AA032683
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $248,844 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), effective September 1, 2025, through August 31, 2028. Under this award, the institution will develop and validate blood-based RNA biomarkers for identifying, diagnosing, and monitoring treatment response in patients with alcohol use disorder (AUD). Building on...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $653,214 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded May 1, 2026, with completion targeted for January 31, 2031. This research project investigates the mechanisms by which adolescent binge drinking induces long-term cognitive deficits in adulthood through proinflammatory signaling and epigenetic suppression...
- Federal Grant Award Summary Emory University received a $755,539 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 10, 2025, with completion by May 31, 2030. This research project generates real-world evidence on the utilization, effectiveness, and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treating alcohol use disorder (AUD). Using administrative claims data and linked...
- Federal Grant Award Summary RTI International received a $901,666 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded September 20, 2025, with completion targeted for June 30, 2030. The grant supports the development of small molecule negative allosteric modulators (NAMs) targeting the RXFP3 receptor as a novel pharmacological treatment for alcohol use disorder (AUD). The research team is optimizing lead...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $2.55 million Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), effective September 5, 2025, with a completion date of August 31, 2029. The award supports a four-year research initiative investigating the insula-bed nucleus of the stria terminalis (BNST) neural circuit's role in alcohol use disorder (AUD) development. The...
- Federal Grant Award Summary Funding Agency: National Institute on Alcohol Abuse and Alcoholism (NIAAA) Federal Grant Program: Alcohol Research Programs (CFDA 93.273) Award Amount: $559,180 Award Date: September 1, 2025 Project Period: September 1, 2025 – June 30, 2030 Awardee: RTI International (Research Triangle Institute), Research Triangle Park, North Carolina RTI International will conduct multi-omic research to identify neurobiological factors underlying alcohol use disorder (AUD) with...
- Federal Project Grant Award Summary Drexel University received a $564,306 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) effective May 1, 2026 through January 31, 2031. The award supports research investigating the suppression of ethanol dependence-induced maladaptive behavioral and consumption patterns through modulation of the glucagon-like peptide-1 (GLP-1) system. The research employs a chronic...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded the University of Tennessee Health Science Center a Project Grant totaling $399,076 (awarded September 15, 2025; completion date August 31, 2027) under the Alcohol Research Programs (CFDA 93.273). The project focuses on developing a rapid screening platform for identifying and repurposing FDA-approved drugs to treat alcohol use disorder (AUD) and address chronic alcohol tolerance. Using the...
- Federal Project Grant Award Summary Wake Forest University Health Sciences received a $647,330 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), awarded on September 12, 2025, with an ultimate completion date of July 31, 2030. The grant funds a longitudinal research initiative examining epigenetic profiles in the alcohol-naive primate cortex to identify biological risk factors predisposing individuals to alcohol...
- Federal Grant Award Summary The National Institute on Alcohol Abuse and Alcoholism (NIAAA) under its Alcohol Research Programs (CFDA 93.273) awarded $585,073 to the University of North Carolina at Chapel Hill, with an award date of September 20, 2025 and completion date of August 31, 2028. This Project Grant supports research to develop and validate an innovative Fetal Alcohol Spectrum Disorders (FASD) risk assessment tool that integrates maternal and paternal risk factors with novel measures of...
The University of North Carolina at Chapel Hill received a $444,576 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to evaluate the efficacy of glucagon-like peptide-1 receptor agonist (GLP-1RA) compounds and related medications in reducing alcohol use disorder (AUD). The award, effective May 1, 2026, through January 31, 2031, supports a preclinical screening pipeline designed to assess how three FDA-approved compounds—semaglutide (GLP-1RA), tirzepatide (GLP-1RA/glucose-dependent insulinotropic polypeptide dual agonist), and retatrutide (triple agonist)—affect alcohol interoceptive effects and drinking behavior in self-administration models using an alcohol versus sucrose choice procedure. The research deliverables include behavioral testing assessing alcohol subjective and reinforcement effects (Aims 1-2) and advanced neuroimaging analyses using functional MRI and fiber photometry to evaluate the impact of the most efficacious GLP-1RA on salience network activity. This translational research directly addresses the emerging clinical observation that GLP-1RA medications may reduce alcohol consumption, with the goal of identifying optimal candidate compounds for future clinical trials in individuals with AUD. The project advances NIAAA's mission to develop improved treatment methodologies and prevention strategies for alcohol-related disorders through systematic preclinical investigation of promising pharmaceutical interventions.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $444.6k | 5/7/26 |